Table 4.
Overview of currently published literature on 225Ac-PSMA-617 TAT
| Author | N | Treatment cycles (range) |
Any PSA decline | >50% PSA fall | OS (months) | PFS (months) | CRR (%) | Administered Activity | ECOG Performance status |
|---|---|---|---|---|---|---|---|---|---|
| Kratochwil et al. 1 | 2 | 1 - 3 | 2 | 2 | - | - | - | 100 KBq/Kg | - |
| Kratochwil et al. 9 | 14 | - | - | - | - | - | - | 50 - 100 KBq/Kg | - |
| Kratochwil et al. 11 | 38 | - | 33/38 (87%) | 24/38 (63%) | >12 | 7 | 5/38 (13%) | 100 KBq/Kg | 0/1 - 31 (80%) ≥2 - 7 (20%) |
| Sathekge et al. 12 | 17 | 11patients (2 - 3 cycles) 6 patients (>3 cycles) |
- | 14/17 (82%) | - | - | - | 8-6 & 4 MBq | 0/1 - 15 (88%) 2 - 2 (12%) |
| Sathekge et al. 19 | 73 | - | 83% | 70 % | 18 (16.2 -19.9) | 15.2 (13.1 - 17.4) | 21/73 (29%) | 8 - 6 & 4 MBq | 0/1 - 82% ≥2 - 18% |
| Khreish et al. 21 | 20 | 1 (tandem 225Ac +177Lu-PSMA-617 | 16/20 (80%) | 13/20 (65%) | 12 (1 - 23) |
4.9 (3 - 6.5) | 60 KBq/Kg (20 - 84) |
0/1 - 12 (60%) 2 - 8 (40%) |
|
| Current Study | 28 | 1 - 7 | 22/28 (78.6%) | 11/28 (39%) | 17 (16 - upper limit not reached) |
12 (9 - 13) | 2/22 (9%) | 100 KBq/Kg | 0/1 - 2 (7%) 2 - 6 (21%) 3 - 15 (54%) 4 - 5 (18%) |
N: number of patients; PSA: Prostate specific antigen, OS: Overall survival, PFS: Progression-free survival, CRR: Complete response rate, KBq/Kg: Kilobecquerel per kilogram, MBq: Megabecquerel, ECOG performance status: Eastern Cooperative Oncology Group.